The value of thioredoxin family proteins and proliferation markers in dysplastic and malignant gallbladders in patients with primary sclerosing cholangitis

Digestive Diseases and Sciences

Volumn 57, Issue 5, 2012, Pages 1163-1170

  Said, Karouk ^a   Bergquist, Annika ^a   Glaumann, Hans ^a   Björnstedt, Mikael ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dysplasia; Gallbladder; Gallbladder carcinoma; Glutathione reductase; Primary sclerosing cholangitis; Thioredoxin

Indexed keywords

CYCLIN D1; GLUTAREDOXIN 1; GRX1 PROTEIN; KI 67 ANTIGEN; MEMBRANE PROTEIN; PROTEIN P53; THIOREDOXIN; THIOREDOXIN 1; THIOREDOXIN REDUCTASE 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GLUTAREDOXIN; GLUTATHIONE; GLUTATHIONE REDUCTASE; ISOPROTEIN;

ADULT; CELL PROLIFERATION; CHOLECYSTITIS; DYSPLASIA; FEMALE; FIBROSIS; GALBLADDER FIBROSIS; GALLBLADDER CARCINOMA; GALLBLADDER DISEASE; GALLBLADDER MALFORMATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; AGED; ARTICLE; BILE DUCT TUMOR; DOWN REGULATION; EARLY DIAGNOSIS; EPITHELIUM; GALLBLADDER; GALLBLADDER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PRECANCER; PREDICTIVE VALUE; SCLEROSING CHOLANGITIS;

ADULT; AGED; BILE DUCT NEOPLASMS; BIOLOGICAL MARKERS; CHOLANGITIS, SCLEROSING; DOWN-REGULATION; EARLY DETECTION OF CANCER; EPITHELIUM; FEMALE; GALLBLADDER; GALLBLADDER NEOPLASMS; GLUTAREDOXINS; GLUTATHIONE; GLUTATHIONE REDUCTASE; HUMANS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; PROTEIN ISOFORMS; THIOREDOXIN REDUCTASE 1; THIOREDOXINS;

EID: 84863629368     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2089-4     Document Type: Review

References (37)

1. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL. Current concepts. Primary sclerosing cholangitis. N Engl J Med. 1984; 310:899-903.
2. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol. 2008;48: 598-605.
3. Buckles DC, Lindor KD, Larusso NF, Petrovic LM, Gores GJ. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol. 2002;97:1138-1142.
4. Leung UC, Wong PY, Roberts RH, Koea JB. Gall bladder polyps in sclerosing cholangitis: does the 1-cm rule apply? ANZ J Surg. 2007;77:355-357.
5. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002; 36:321-327.
6. Pan JS, Hong MZ, Ren JL. Reactive oxygen species: a doubleedged sword in oncogenesis. World J Gastroenterol. 2009;15: 1702-1707.
7. Abraham SC, Cruz-Correa M, Argani P, Furth EE, Hruban RH, Boitnott JK. Diffuse lymphoplasmacytic chronic cholecystitis is highly specific for extrahepatic biliary tract disease but does not distinguish between primary and secondary sclerosing cholangiopathy. Am J Surg Pathol. 2003;27:1313-1320.
8. Jeffrey GP, Reed WD, Carrello S, Shilkin KB. Histological and immunohistochemical study of the gall bladder lesion in primary sclerosing cholangitis. Gut. 1991;32:424-429.
9. Jessurun J, Bolio-Solis A, Manivel JC. Diffuse lymphoplasmacytic acalculous cholecystitis: a distinctive form of chronic cholecystitis associated with primary sclerosing cholangitis. Hum Pathol. 1998;29:512-517.
10. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for ametaplasia-dysplasiacarcinoma sequence. Am J Surg Pathol. 2007;31:907-913.
11. Rizzi PM, Ryder SD, Portmann B, Ramage JK, Naoumov NV, Williams R. p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut. 1996;38:265-268.
12. Sugimachi K, Aishima S, Taguchi K, et al. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. J Hepatol. 2001;35:74-79.
13. Urig S, Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol. 2006;16: 452-465.
14. Gromer S, Urig S, Becker K. The thioredoxin system-from science to clinic. Med Res Rev. 2004;24:40-89.
15. Lillig CH, Berndt C, Holmgren A. Glutaredoxin systems. Biochim Biophys Acta. 2008;1780:1304-1317.
16. Rundlof AK, Fernandes AP, Selenius M, et al. Quantification of alternative mRNA species and identification of thioredoxin reductase 1 isoforms in human tumor cells. Differentiation. 2007;75: 123-132.
17. Olm E, Jonsson-Videsater K, Ribera-Cortada I, et al. Selenite is a potent cytotoxic agent for human primary AML cells. Cancer Lett. 2009;282:116-123.
18. Fernandes AP, Capitanio A, Selenius M, Brodin O, Rundlof AK, Bjornstedt M. Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation with proliferation and differentiation. Histopathology. 2009;55:313-320.
19. Lillig CH, Holmgren A. Thioredoxin and related molecules-from biology to health and disease. Antioxid Redox Signal. 2007;9:25-47.
20. Yoon BI, Kim YH, Yi JY, et al. Expression of thioredoxin during progression of hamster and human cholangiocarcinoma. Cancer Sci. 2010;101:281-288.
21. Cunnea P, Fernandes AP, Capitanio A, Eken S, Spyrou G, Bjornstedt M. Increased expression of specific thioredoxin family proteins; a pilot immunohistochemical study on human hepatocellular carcinoma. Int J Immunopathol Pharmacol. 2007;20: 17-24.
22. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM. The thioredoxin- thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 2003;23:2425-2433.
23. Yoon BI, Kim DY, Jang JJ, Han JH. Altered expression of thioredoxin reductase-1 in dysplastic bile ducts and cholangiocarcinoma in a hamster model. J Vet Sci. 2006;7:211-216.
24. Fleming KA, Boberg KM, Glaumann H, Bergquist A, Smith D, Clausen OP. Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2001;34:360-365.
25. Hameed O, Adams AL, Baker AC, et al. Using a higher cutoff for the percentage of HER2 ? cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis. Am J Clin Pathol. 2008;130:425-427.
26. Atkinson R, Fau-Mollerup J, Mollerup J, et al. Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation. 20110803 DCOM- 20110927(1543-2165 (Electronic)).
27. Bjornsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134:975-980.
28. Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat. 1998;49:195-208.
29. Menke A, Adler G. TGFbeta-induced fibrogenesis of the pancreas. Int J Gastrointest Cancer. 2002;31:41-46.
30. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132: 2557-2576.
31. Cutroneo KR, White SL, Chiu JF, Ehrlich HP. Tissue fibrosis and carcinogenesis: divergent or successive pathways dictate multiple molecular therapeutic targets for oligo decoy therapies. J Cell Biochem. 2006;97:1161-1174.
32. BathejaN, Suriawinata A, Saxena R, IonescuG, SchwartzM, Thung SN. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis. Mod Pathol. 2000;13:1265-1268.
33. Bergquist A, Glaumann H, Stal P, Wang GS, Broome U. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma. J Intern Med. 2001;249:69-75.
34. Hui AM, Li X, Shi YZ, Takayama T, Torzilli G, Makuuchi M. Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. Clin Cancer Res. 2000;6: 4272-4277.
35. Itoi T, Shinohara Y, Takeda K, et al. Nuclear cyclin D1 overexpression is a critical event associated with cell proliferation and invasive growth in gallbladder carcinogenesis. J Gastroenterol. 2000;35:142-149.
36. Orban TI, Olah E. Emerging roles of BRCA1 alternative splicing. Mol Pathol. 2003;56:191-197.
37. Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995;55: 3140-3148.